These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12434726)

  • 21. Overview of randomized clinical trials of lipid intervention for atherosclerotic cardiovascular disease.
    Buchwald H; Fitch L; Moore RB
    Control Clin Trials; 1982 Sep; 3(3):271-83. PubMed ID: 6759035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid-lowering trials: results and limitations.
    Furberg CD
    Am Heart J; 1994 Dec; 128(6 Pt 2):1304-8. PubMed ID: 7977011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between short-term simvastatin therapy before coronary artery bypass grafting and postoperative myocardial blood flow as assessed by positron emission tomography.
    Dotani MI; Morise AP; Haque R; Jain AC; Gupta N; Gibson CM
    Am J Cardiol; 2003 May; 91(9):1107-9. PubMed ID: 12714156
    [No Abstract]   [Full Text] [Related]  

  • 25. Achieving blood lipid goals in patients with coronary artery disease.
    McKenney JM
    Am J Health Syst Pharm; 2001 Mar; 58(5):415-9. PubMed ID: 11258179
    [No Abstract]   [Full Text] [Related]  

  • 26. Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group.
    Waksman R; Kosinski AS; Klein L; Boccuzzi SJ; King SB; Ghazzal ZM; Weintraub WS
    Am J Cardiol; 1996 Jul; 78(2):221-4. PubMed ID: 8712148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
    Blankenhorn DH; Nessim SA; Johnson RL; Sanmarco ME; Azen SP; Cashin-Hemphill L
    JAMA; 1987 Jun; 257(23):3233-40. PubMed ID: 3295315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study.
    Brown BG; Hillger L; Zhao XQ; Poulin D; Albers JJ
    Ann N Y Acad Sci; 1995 Jan; 748():407-17; discussion 417-8. PubMed ID: 7695184
    [No Abstract]   [Full Text] [Related]  

  • 29. The surgeon's role in optimizing medical therapy and maintaining compliance with secondary prevention guidelines in patients undergoing coronary artery bypass grafting.
    Lazar HL
    J Thorac Cardiovasc Surg; 2020 Sep; 160(3):691-698. PubMed ID: 31843228
    [No Abstract]   [Full Text] [Related]  

  • 30. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now.
    Fonarow GC; Ballantyne CM
    Circulation; 2001 Jun; 103(23):2768-70. PubMed ID: 11401927
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacologic prevention of coronary artery disease. What do clinical trials show?
    Milani RV; Lavie CJ
    Postgrad Med; 1996 Feb; 99(2):109-12, 115-20. PubMed ID: 8632961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serial quantitative coronary angiography and coronary events.
    Mack WJ; Xiang M; Selzer RH; Hodis HN
    Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase.
    Kappetein AP; Dawkins KD; Mohr FW; Morice MC; Mack MJ; Russell ME; Pomar J; Serruys PW
    Eur J Cardiothorac Surg; 2006 Apr; 29(4):486-91. PubMed ID: 16497510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When is percutaneous coronary intervention a better choice than coronary artery by-pass grafting?
    Kukreja N; Serruys PW
    Pol Arch Med Wewn; 2008 Mar; 118(3):98-9. PubMed ID: 18476454
    [No Abstract]   [Full Text] [Related]  

  • 36. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis.
    Hodis HN; Mack WJ; LaBree L; Cashin-Hemphill L; Sevanian A; Johnson R; Azen SP
    JAMA; 1995 Jun; 273(23):1849-54. PubMed ID: 7776501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Keeping vessels clear after bypass surgery.
    Harv Heart Lett; 2000 Dec; 11(4):5-6. PubMed ID: 11114793
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of niacin, statins, and resins in patients with combined hyperlipidemia.
    Brown BG; Zambon A; Poulin D; Rocha A; Maher VM; Davis JW; Albers JJ; Brunzell JD
    Am J Cardiol; 1998 Feb; 81(4A):52B-59B. PubMed ID: 9526815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-benefit analysis of lipid lowering therapy.
    Davie AP; McMurray JJ
    Eur Heart J; 1996 Jul; 17(7):974-5. PubMed ID: 8809507
    [No Abstract]   [Full Text] [Related]  

  • 40. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.
    Oparil S
    Hypertension; 2003 May; 41(5):1006-9. PubMed ID: 12695423
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.